VCAN has been identified as a biomarker for tumour metastasis and chemotherapy resistance [293,294,295,296], assisting in the monitoring of off-target effects of platinum (Pt)-based chemotherapy and facilitating timely adjustments to therapeutic strategies [294]. The gene discussed is VCAN; the disease is neoplasm.